The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)

The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r) - The efficacy of Mesarazine drugs treatment for clinical relapse in ulcerative colitis patients, compared 3600mg of Asacolo(r) with 4000mg Pentasa(r)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009937

Enrollment

Registered

2013-02-05

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Oral administration of Asacolo 3600mg/day or Pentasa 4000mg/day Oral administration of Asacolo 3600mg/day or Pentasa 4000mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The relapse UC patients with oral intake of Asacolol less than 3600mg/day or Pentasa less than 4000mg. Agreement about this study Over 16 years

Exclusion criteria

Exclusion criteria: Over daily ten times of diarhea The patients who are considerd inapproval for this study by their outhospital doctors

Design outcomes

Primary

Measure	Time frame
CAI score EI score Endoscopic examination( biopsy) Blood test	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026